Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-08-02
2005-08-02
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S177000, C514S178000, C514S179000, C514S182000, C514S885000
Reexamination Certificate
active
06924274
ABSTRACT:
Lupus erythematosus can be treated by administering therapeutic amounts of Δ5-androstene-3β-ol-7,17-dione and metabolizable precursors thereof, such as Δ5-androstene-3b-acetoxy-7,17-dione, which are readily metabolized in vivo to Δ5-androstene-3β-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
REFERENCES:
patent: 3107256 (1963-10-01), Harnik
patent: 4628052 (1986-12-01), Peat
patent: 4812447 (1989-03-01), Roberts
patent: 5292730 (1994-03-01), Lardy
patent: 5296481 (1994-03-01), Partridge et al.
patent: 5567696 (1996-10-01), McGuire et al.
patent: 5585371 (1996-12-01), Lardy
patent: 5763433 (1998-06-01), Morfin
patent: 6372732 (2002-04-01), Lardy et al.
patent: 6593316 (2003-07-01), Lardy et al.
patent: 09151197 (1997-10-01), None
patent: WO 94/03176 (1994-02-01), None
patent: WO 94/08589 (1994-04-01), None
patent: WO99/25333 (1999-05-01), None
Loria, R., “Mobilization of cutaneous immunity for systemic protection against infections,” Ann N Y Acad Sci, 650: 363-6 (1992).
Mitchell, Eddie E., “Addressing the regio- and stereo-selectivity seen in P4502A5 mutants with DHEA”, dissertation in partial fulfillment of the requirements of the degree of Doctor of Philosophy at the University of Kentucky, Lexington, Kentucky (1996).
Su, Ching-Yuan, “Induction of hepatic mitochondrial glycerophosphate dehydrogenase and malic enzyme 1. Effects of Dehydroepiandrosterone 2. Effects of dehydroepiandrosterone-related steroids and cytochrome P-450 inducers”, thesis submitted in partial fulfillment of the requirements of the degree of Doctor of Philosophy, University of Wisconsin-Madison, Madison, Wisconsin (1988).
Padgett, David Andrew, “Regulation of the immune system and its response to infection with dehydroepiandrosterone, androstenediol, and androstenetriol”, dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University, Richmond, Virginia (1994).
Whitcomb, Jeannette Marie, “Effects of dehydroepiandrosterone, DHEA-analogs and food restriction on free radical reactions and autoimmunity in the MRL/1pr mouse”, dissertation in partial fulfillment of the requirements of the degree of Doctor of Philosophy, Temple University, Ann Arbor, Michigan (1988).
L. Stárka et al., 7-Hydroxylation of Dehydroepiandrosterone by rat-liver homogenate,Biochim. Biophys. ACTA56:76-82 1962.
A. M. Bongiovanni, Digitonin precipitable steroids in normal human urine,Journal Clinical Endocrinology Metabolism26:1240-1244 1966.
Lardy Henry A.
Weeks Charles E.
Henley III Raymond J.
Humanetic Corp.
Sherrill Law Offices PLLC
LandOfFree
Use of Δ5-androstene-3β-ol-7,17-dione in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of Δ5-androstene-3β-ol-7,17-dione in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of Δ5-androstene-3β-ol-7,17-dione in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3465615